CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia

oleh: Davide Rossi, Antonella Zucchetto, Francesca Maria Rossi, Daniela Capello, Michaela Cerri, Clara Deambrogi, Stefania Cresta, Silvia Rasi, Lorenzo De Paoli, Chiara Lobetti Bodoni, Pietro Bulian, Giovanni Del Poeta, Marco Ladetto, Valter Gattei, Gianluca Gaidano

Format: Article
Diterbitkan: Ferrata Storti Foundation 2008-10-01

Deskripsi

Identification of prognosticators for Binet A chronic lymphocytic leukemia is important for selecting patients with dismal prognosis. We analyzed CD49d expression in 140 consecutive Binet A chronic lymphocytic leukemia. At diagnosis, CD49d ≥30% (54/140, 38.6%) associated with proliferation markers, namely CD38 ≥30% (p=3.9×10−6), LDH (p=0.007) and β2-microglobulin (p=0.020). Univariate log-rank analysis identified CD49d ≥30% as a risk factor of treatment free survival (p=8.3x10−5), time to progression to a more advanced stage (p=4.7×10−4), and time to lymphocyte doubling (p=0.009). Multivariate analysis selected CD49d ≥30% as an independent treatment free survival predictor after adjustment for biological (HR 2.28; 95% CI 1.71–4.45, p=0.015) and both biological and clinical variables analyzed together (HR 3.33, 95% CI 1.61–6.90, p=0.001). Within Binet A subgroups harboring favorable biological variables (IGHV homology